SERA PROGNOSTICS REPORTS 2ND QUARTER 2022 FINANCIAL RESULTS.

SALT LAKE CITY: Sera Prognostics Inc., The Pregnancy Company(r) (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended June 30, 2022.

Recent Highlights:

Executed on Sera's strategy of pursuing healthcare systems where administrative and clinical leadership are aligned on incorporating PreTRM testing efficiently as an add-on to comprehensive services provided to pregnant women.

Contracted with several new self-insured employer plans to incorporate PreTRM testing as an advanced pregnancy benefit.

Demonstrated improved performance of the PreTRM test over an expanded time window for collecting blood, now from 18-20 weeks, allowing physicians to more easily schedule patients for preterm risk evaluation.

Showed a sensitivity of nearly 90% for spontaneous preterm delivery risk prediction and a very high negative predictive value of 99% in a patient whose PreTRM test is interpreted to be "Lower Risk".

Streamlined operations to meet our commercial plans, expand adoption of the PreTRM(r) Test and enable the Company to extend its operations into 2026 without the need for additional financing.

"We see a sizeable opportunity to increase awareness of our PreTRM(r) Test and build adoption within a variety of health systems," said Gregory C. Critchfield, MD, MS, Chairman and CEO of Sera Prognostics. "As example of many such systems, we are making demonstrable progress in contracting with self-insured employers who become adopters because they see the immediate value in managing escalating healthcare costs and offering important benefits to attract and retain talented employees. We anticipate additional clinical and health economic publications that further illustrate the clinical utility and benefit of PreTRM(r) technology, supporting the achievement of our vision to improve the well-being of mothers and newborns and decreasing healthcare costs."

Second Quarter 2022 Financial Results

Second quarter 2022 revenue of $78,000 compared to $20,000 for the same period of 2021.

Total operating expenses were $11.8 million, up from $7.4 million for the second quarter of 2021.

Research and development expenses for the second quarter of 2022 were $3.3 million compared to $2.8 million for the second quarter of 2021 due primarily to increased laboratory operations and clinical study costs.

Selling, general and...